Newsroom

Industry News

28 Nov

CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

NEWARK, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for indications with high unmet medical need, including rare and orphan diseases, today announced that management will participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare...

Read more

23 Nov

Ecolab Schedules Webcast of Industry Conference for November 29

ST. PAUL, Minn.–(BUSINESS WIRE)– Ecolab Inc. Chief Financial Officer Daniel J. Schmechel will address financial analysts at the Citi Basic Materials Conference on Tuesday, Nov. 29 in New York. Ecolab will host a live webcast of Mr. Schmechel’s presentation. Details for the webcast are as follows: TIME: 10:15 a.m....

Read more

23 Nov

Cellectar Biosciences Announces Pricing of $8,000,000 Public Offering

MADISON, Wis., Nov. 23, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB) (“Cellectar” or the “company”), an oncology-focused, clinical stage biotechnology company, today announces the pricing of an underwritten public offering of shares of its common stock, or in lieu thereof, shares of its preferred stock convertible into 66,667...

Read more

22 Nov

Actinium Issues Letter to Shareholders Highlighting 2016 Accomplishments and Anticipated Milestones for 2017

NEW YORK, Nov. 22, 2016 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that it has issued a letter to shareholders highlighting the Company’s accomplishments in 2016 and anticipated milestones...

Read more

22 Nov

BioLineRx Reports Third Quarter 2016 Financial Results

TEL AVIV, Israel, Nov. 22, 2016 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the third quarter ended September 30, 2016. Highlights and achievements during third quarter of 2016 and to...

Read more

22 Nov

Protea Announces Third Quarter 2016 Results

MORGANTOWN, W.Va., Nov. 22, 2016 (GLOBE NEWSWIRE) — Protea Biosciences Group, Inc. (PRGB) (“Protea”) released its Third Quarter 2016 results today, reporting revenue of $519,908 for the quarter, and revenue for the first nine months of 2016 of $1,577,010, an increase of 24% over the first nine months of...

Read more

Page 20 of 216« First...10...1819202122...304050...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address